Human interleukin-2 receptor β mutations associated with defects in immunity and peripheral tolerance.


Journal

The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R

Informations de publication

Date de publication:
03 06 2019
Historique:
received: 13 12 2018
revised: 21 02 2019
accepted: 04 04 2019
pubmed: 2 5 2019
medline: 15 4 2020
entrez: 2 5 2019
Statut: ppublish

Résumé

Interleukin-2, which conveys essential signals for immunity, operates through a heterotrimeric receptor. Here we identify human interleukin-2 receptor (IL-2R) β chain (

Identifiants

pubmed: 31040185
pii: jem.20182304
doi: 10.1084/jem.20182304
pmc: PMC6547869
doi:

Substances chimiques

IL2RB protein, human 0
Interleukin-2 Receptor beta Subunit 0
STAT3 Transcription Factor 0
STAT5 Transcription Factor 0

Banques de données

PDB
['2B5I', '5M5E']

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1311-1327

Subventions

Organisme : Wellcome Trust
ID : 101908/Z/13/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 207556/Z/17/Z
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 083650/Z/07/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 099966/Z/12/Z
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.

Références

Mol Cell Biol. 1999 Mar;19(3):1910-8
pubmed: 10022878
Blood. 2001 Aug 1;98(3):877-9
pubmed: 11468191
Immunity. 2002 Aug;17(2):167-78
pubmed: 12196288
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Nat Immunol. 2005 Nov;6(11):1142-51
pubmed: 16227984
Science. 2005 Nov 18;310(5751):1159-63
pubmed: 16293754
Blood. 2006 Mar 15;107(6):2409-14
pubmed: 16304057
Science. 1992 Jul 17;257(5068):379-82
pubmed: 1631559
Science. 2006 Mar 31;311(5769):1924-7
pubmed: 16484453
Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5941-6
pubmed: 16585503
Nat Rev Immunol. 2006 Aug;6(8):595-601
pubmed: 16868550
J Allergy Clin Immunol. 2007 Feb;119(2):482-7
pubmed: 17196245
Eur Cytokine Netw. 2008 Mar;19(1):49-59
pubmed: 18299274
Nature. 1991 Oct 31;353(6347):858-61
pubmed: 1944559
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3058-63
pubmed: 20133667
Proteins. 2010 Jun;78(8):1950-8
pubmed: 20408171
Blood. 2010 Nov 11;116(19):3865-74
pubmed: 20733159
N Engl J Med. 2010 Sep 23;363(13):1211-1221
pubmed: 20860503
Blood. 2012 Mar 15;119(11):2665-74
pubmed: 22180440
Nat Rev Immunol. 2012 Feb 17;12(3):180-90
pubmed: 22343569
Nature. 2012 Mar 25;484(7395):529-33
pubmed: 22446627
Immunity. 2013 Jan 24;38(1):13-25
pubmed: 23352221
Nat Genet. 2013 Jun;45(6):664-9
pubmed: 23603761
Mol Ther. 2014 Jul;22(7):1388-1395
pubmed: 24686272
Immunity. 2015 Mar 17;42(3):431-42
pubmed: 25786175
Immunity. 2015 Mar 17;42(3):443-56
pubmed: 25786176
Immunity. 2015 Aug 18;43(2):394-407
pubmed: 26287684
Science. 1989 May 5;244(4904):551-6
pubmed: 2785715
Am J Med Genet A. 2017 May;173(5):1219-1225
pubmed: 28317311
Oncoimmunology. 2017 Jan 11;6(3):e1277306
pubmed: 28405498
Nat Commun. 2017 May 12;8:15373
pubmed: 28497796
Cancer Immunol Res. 2017 Oct;5(10):929-938
pubmed: 28842470
J Immunol. 2018 Jan 1;200(1):110-118
pubmed: 29187589
Science. 2018 Mar 2;359(6379):1037-1042
pubmed: 29496879
Signal Transduct Target Ther. 2018 Jan 19;3:2
pubmed: 29527328
Immunity. 1995 Oct;3(4):521-30
pubmed: 7584142
Science. 1995 Jun 9;268(5216):1472-6
pubmed: 7770771
J Exp Med. 1997 Feb 3;185(3):499-505
pubmed: 9053450
Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3168-71
pubmed: 9096364

Auteurs

Zinan Zhang (Z)

Cambridge Institute of Therapeutic Immunology and Infectious Disease, and the Department of Medicine, University of Cambridge, Cambridge, UK.
Molecular Development of the Immune System Section, Laboratory of Immune System Biology and Clinical Genomics Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Harvard Medical School, Boston, MA.

Florian Gothe (F)

Institute of Cellular Medicine, Newcastle University, Newcastle, UK.
Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany.

Perrine Pennamen (P)

University of Bordeaux, Maladies Rares: Génétique et Métabolisme Institut National de la Santé et de la Recherche Médicale U1211, Centre Hospitalier Universitaire de Bordeaux, Service de Génétique Médicale, Bordeaux, France.

John R James (JR)

Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK.

David McDonald (D)

Institute of Cellular Medicine, Newcastle University, Newcastle, UK.

Carlos P Mata (CP)

Cambridge Institute of Therapeutic Immunology and Infectious Disease, and the Department of Medicine, University of Cambridge, Cambridge, UK.
Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK.

Yorgo Modis (Y)

Cambridge Institute of Therapeutic Immunology and Infectious Disease, and the Department of Medicine, University of Cambridge, Cambridge, UK.
Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK.

Anas M Alazami (AM)

Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Meghan Acres (M)

Institute of Cellular Medicine, Newcastle University, Newcastle, UK.

Wolfram Haller (W)

Birmingham Children's Hospital, Birmingham, UK.

Claire Bowen (C)

Birmingham Children's Hospital, Birmingham, UK.

Rainer Döffinger (R)

Department of Clinical Biochemistry and Immunology, Cambridge University Hospital, Cambridge, UK.

Jan Sinclair (J)

Starship Children's Hospital, Auckland, New Zealand.

Shannon Brothers (S)

Starship Children's Hospital, Auckland, New Zealand.

Yu Zhang (Y)

Molecular Development of the Immune System Section, Laboratory of Immune System Biology and Clinical Genomics Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Helen F Matthews (HF)

Molecular Development of the Immune System Section, Laboratory of Immune System Biology and Clinical Genomics Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Sophie Naudion (S)

University of Bordeaux, Maladies Rares: Génétique et Métabolisme Institut National de la Santé et de la Recherche Médicale U1211, Centre Hospitalier Universitaire de Bordeaux, Service de Génétique Médicale, Bordeaux, France.

Fanny Pelluard (F)

Department of Pathology, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France.

Huda Alajlan (H)

Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Yasuhiro Yamazaki (Y)

Immune Deficiency Genetics Section, Laboratory of Clinical Immunology and Microbiology and Clinical Genomics Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Luigi D Notarangelo (LD)

Immune Deficiency Genetics Section, Laboratory of Clinical Immunology and Microbiology and Clinical Genomics Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

James E Thaventhiran (JE)

Cambridge Institute of Therapeutic Immunology and Infectious Disease, and the Department of Medicine, University of Cambridge, Cambridge, UK.

Karin R Engelhardt (KR)

Institute of Cellular Medicine, Newcastle University, Newcastle, UK.

Hamoud Al-Mousa (H)

Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Sophie Hambleton (S)

Institute of Cellular Medicine, Newcastle University, Newcastle, UK sophie.hambleton@newcastle.ac.uk.
Great North Children's Hospital, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle, UK.

Caroline Rooryck (C)

University of Bordeaux, Maladies Rares: Génétique et Métabolisme Institut National de la Santé et de la Recherche Médicale U1211, Centre Hospitalier Universitaire de Bordeaux, Service de Génétique Médicale, Bordeaux, France.

Kenneth G C Smith (KGC)

Cambridge Institute of Therapeutic Immunology and Infectious Disease, and the Department of Medicine, University of Cambridge, Cambridge, UK kgcs2@cam.ac.uk.

Michael J Lenardo (MJ)

Molecular Development of the Immune System Section, Laboratory of Immune System Biology and Clinical Genomics Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD MLENARDO@niaid.nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH